Monograph Details
|
|
Ob/Gyn
> Labor and delivery
|
|
PITOCIN |
| Manufacturer |
|
JHP Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Oxytocin 10Units/mL; IV or IM inj. |
| Indications |
|
Initiation or improvement of uterine contractions in vaginal delivery. Adjunct in abortion. Control of postpartum bleeding. |
| Children |
|
Not applicable. |
| Adults |
|
Induction of labor: individualize. Initially 0.5–1milliunit/minute (see literature); adjust by 1–2 milliunits/minute at 30–60 minute intervals. Usual max at term: 9–10 milliunits/minute. Bleeding: IV, see literature. IM: 10Units after delivery of placenta. Abortion: see literature. |
| Contraindications |
|
Cephalopelvic disproportion. Unfavorable fetal position. When surgical intervention necessary. Fetal distress if labor is not imminent. Unsatisfactory progress in presence of adequate uterine activity. Hyperactive or hypertonic uterus. Invasive cervical carcinoma, active herpes genitalis, total placenta previa, vasa previa, cord presentation or prolapse or other cases where vaginal delivery is contraindicated or if predisposition for uterine rupture exists. All for anteparum use. |
| Precautions |
|
Use only in presence of qualified personnel. Monitor intrauterine pressure, fetal heart rate, maternal blood pressure. |
| Interactions |
|
Avoid use within 4 hours of prophylactic vasoconstriction with caudal block anesthesia. Avoid cyclopropane anesthetics. |
| Adverse Reactions |
|
Maternal: anaphylaxis, postpartum hemorrhage, arrhythmias, fatal afibrinogenemia, nausea, vomiting, pelvic hematoma, water intoxication, hypersensitivity resulting in uterine hypertonicity, spasm, tetany, or rupture. Fetal: bradycardia, arrhythmias, CNS damage, low Apgar scores, jaundice, retinal hemorrhage, death. |
| How Supplied |
Single-dose vial (1mL)—25
Multi-dose vial (10mL)—1 |
|
|
|
|
